Get the Stockscreener App
2.92
3.31%
-0.10
After Hours:
2.63
-0.29
-9.93%
InspireMD Inc. stock is traded at $2.92, with a volume of 140.99K.
It is down -3.31% in the last 24 hours and up +19.18% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$3.02
Open:
$3.02
24h Volume:
140.99K
Relative Volume:
3.70
Market Cap:
$76.60M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-1.4974
EPS:
-1.95
Net Cash Flow:
$-16.76M
1W Performance:
+10.61%
1M Performance:
+19.18%
6M Performance:
+14.96%
1Y Performance:
+17.27%
1-Day Range:
$2.62
$3.1299
1-Week Range:
$2.5516
$3.15
52-Week Range:
$1.81
$3.42
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.92 | 76.60M | 6.21M | -19.92M | -16.76M | -1.95 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com - Defense World
InspireMD appoints Scott R. Ward to its Board - Medical Buyer
InspireMD adds medtech veteran Scott Ward to its board By Investing.com - Investing.com Nigeria
InspireMD Appoints Scott R. Ward to Board of Directors - Defense World
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors - Marketscreener.com
InspireMD adds medtech veteran Scott Ward to its board - Investing.com
InspireMD Strengthens Leadership with Scott R. Ward Appointment - TipRanks
InspireMD Announces Appointment of Accomplished Medical - GlobeNewswire
InspireMD Strengthens Board with Ex-Medtronic Executive Ahead of CGuard Prime FDA Decision | NSPR Stock News - StockTitan
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - MarketBeat
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates - MSN
InspireMD Inc (NSPR) Quarterly 10-Q Report - Quartzy
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) - Yahoo Finance
InspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Call Transcript - Insider Monkey
InspireMD Inc. Faces Financial Uncertainty Amidst Ongoing Losses and Cash Flow Challenges - TipRanks
InspireMD Inc. Reports Q3 2024 Financial Results - TipRanks
InspireMD Achieves Record Q3 Revenue with CGuard Success - TipRanks
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InspireMD Sets Revenue Record, Files FDA Approval for CGuard Stent Amid Wider Losses | NSPR Stock News - StockTitan
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... By GuruFocus - Investing.com Canada
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings - Yahoo Finance
InspireMD announces inducement grants - Medical Buyer
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
Inspiremd Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
InspireMD (NSPR) to Release Quarterly Earnings on Tuesday - MarketBeat
InspireMD to Report Third Quarter 2024 Financial Results - GlobeNewswire
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th - The Manila Times
StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR) - MarketBeat
Rosalind Advisors, Inc. Acquires Shares in InspireMD Inc - GuruFocus.com
One InspireMD Insider Raised Stake By 13% In Previous Year - Yahoo Finance
InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com - MarketBeat
10+ things to know in #MiamiTech: News from InspireMD, 1NCE, Flow, UrbanLink, Carve Communications, Miami Dade College, Aleph, Taxfyleand lots of opportunities! - Refresh Miami
InspireMD Expands with New Miami Headquarters - TipRanks
InspireMD Announces Establishment of Global Headquarters in - GlobeNewswire
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System - StockTitan
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent - Yahoo Finance
InspireMD (NSPR) Price Target Increased by 11.49% to 4.95 - MSN
InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com - MarketBeat
InspireMD Advances with FDA Study Approval and Global Goals - Yahoo Finance
FDA approves InspireMD's pivotal carotid stent study - Investing.com
FDA approves InspireMD's pivotal carotid stent study By Investing.com - Investing.com Australia
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System - The Manila Times
InspireMD Announces Approval of Investigational Device - GlobeNewswire
Recent Investment Analysts’ Ratings Updates for InspireMD (NSPR) - Defense World
InspireMD Launches New Employee Inducement Plan - Investing.com
InspireMD Launches 2024 Plan to Attract Talent with Stock - TipRanks
Nantahala Capital Management LLC Sells 39,856 Shares of InspireMD, Inc. (NYSE:NSPR) - Defense World
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):